GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scorpius Holdings Inc (AMEX:SCPX) » Definitions » 3-Year EPS without NRI Growth Rate

Scorpius Holdings (Scorpius Holdings) 3-Year EPS without NRI Growth Rate : -1.20% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Scorpius Holdings 3-Year EPS without NRI Growth Rate?

Scorpius Holdings's EPS without NRI for the three months ended in Dec. 2023 was $-0.24.

During the past 3 years, the average EPS without NRI Growth Rate was -1.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 24.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 44.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Scorpius Holdings was 67.30% per year. The lowest was -24.30% per year. And the median was 36.90% per year.


Competitive Comparison of Scorpius Holdings's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Scorpius Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scorpius Holdings's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scorpius Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Scorpius Holdings's 3-Year EPS without NRI Growth Rate falls into.



Scorpius Holdings 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Scorpius Holdings  (AMEX:SCPX) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Scorpius Holdings 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Scorpius Holdings's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Scorpius Holdings (Scorpius Holdings) Business Description

Industry
Traded in Other Exchanges
Address
627 Davis Drive, Suite 300, Morrisville, NC, USA, 27560
NightHawk Biosciences Inc is a commercial-stage company with a fully integrated ecosystem to accelerate the discovery and development of novel therapies that arm the immune system. By leveraging its proprietary platforms, the company is advancing its first-in-class product portfolio with a focus on cancer and inflammatory and infectious diseases. Its current pipeline has categories: Oncology, immunology and molecular biology.
Executives
Prendergast John K A director ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Jeffrey Alan Wolf director, officer: Chief Executive Officer 3985 RESEARCH PARK DRIVE, ANN ARBOR MI 48108
Smith Edward B Iii director C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
William L. Ostrander officer: CFO/Corp Secy 801 CAPITOLA DRIVE, SUITE 12, DURHAM NC 27713
John J Monahan director
Robert James Jakobs officer: VP Finance/Controller/Secty PO BOX 14487, DURHAM NC 27709
Jeff Tobin Hutchins officer: Chief Scientific Officer 15823 S. 4210 RD., CLAREMORE OK 74017
Ann A Rosar officer: VP of Finance and Controller C/O 801 CAPITOLA DRIVE, DURHAM NC 27713
Michael Kharitonov director 100 EUROPA DRIVE, CHAPEL HILL NC 27517
Timothy J Creech officer: Chief Financial Officer C/O TRIMERIS, INC., 3518 WESTGATE DR. SUITE 300, DURHAM NC 27707
Stephen J. Dipalma officer: Interim CFO C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Aristar Heat, Llc 10 percent owner 1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management, Llc 10 percent owner 1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management Gp, Llc 10 percent owner 1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Taylor Schreiber officer: Vice President of Research 100 EUROPA DRIVE, CHAPEL HILL NC 27517

Scorpius Holdings (Scorpius Holdings) Headlines

From GuruFocus

Heat Biologics Joins Russell Microcap� Index

By Marketwired Marketwired 06-28-2021

Heat Biologics Announces Planned Acquisition of Elusys Therapeutics

By GuruFocusNews GuruFocusNews 12-21-2021